Get the Stockscreener App
13.03
2.08%
+0.265
Enanta Pharmaceuticals Inc stock is currently priced at $13.03, with a 24-hour trading volume of 47,577.
It has seen a +2.08% increased in the last 24 hours and a -22.56% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $12.76 pivot point. If it approaches the $13.07 resistance level, significant changes may occur.
Previous Close:
$12.76
Open:
$12.91
24h Volume:
47,577
Market Cap:
$274.18M
Revenue:
$73.62M
Net Income/Loss:
$-138.24M
P/E Ratio:
-2.0634
EPS:
-6.3125
Net Cash Flow:
$-99.19M
1W Performance:
-6.36%
1M Performance:
-22.56%
6M Performance:
+56.36%
1Y Performance:
-48.96%
1D Range:
$12.81
$13.18
52W Range:
$8.08
$28.25
Enanta Pharmaceuticals Inc Stock (ENTA) Company Profile
Name
Enanta Pharmaceuticals Inc
Sector
Industry
Phone
617-607-0800
Address
500 Arsenal Street, Watertown, MA
Enanta Pharmaceuticals Inc Stock (ENTA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-22 | Initiated | H.C. Wainwright | Buy |
| Jul-06-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Jun-01-22 | Upgrade | Evercore ISI | Underperform → In-line |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Sep-09-21 | Initiated | SVB Leerink | Mkt Perform |
| Jan-29-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Nov-24-20 | Initiated | Evercore ISI | Underperform |
| Aug-28-20 | Resumed | ROTH Capital | Buy |
| Aug-26-20 | Initiated | Piper Sandler | Overweight |
| Jul-27-20 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Mar-17-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Nov-22-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Sep-26-19 | Downgrade | JP Morgan | Neutral → Underweight |
| May-24-19 | Initiated | Wolfe Research | Outperform |
| Apr-23-19 | Upgrade | Berenberg | Hold → Buy |
| Dec-13-18 | Initiated | Berenberg | Hold |
| Jun-06-18 | Initiated | ROTH Capital | Buy |
| Feb-08-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-02-18 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-21-17 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Jul-11-17 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Apr-28-16 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Feb-09-16 | Reiterated | Barclays | Underweight |
| Oct-23-15 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-23-15 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
View All
Enanta Pharmaceuticals Inc Stock (ENTA) Latest News
Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Tops Revenue Estimates
Zacks Investment Research
Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Lags Revenue Estimates
Zacks Investment Research
Strength Seen in Enanta Pharmaceuticals (ENTA): Can Its 13.8% Jump Turn into More Strength?
Zacks Investment Research
The Zacks Analyst Blog Highlights Enanta, OneConnect Financial, KNOT Offshore, Hippo Holdings and H World
Zacks Investment Research
5 Secret Santa Stocks to Pop Surprise Returns
Zacks Investment Research
Wall Street Analysts Predict a 108.12% Upside in Enanta Pharmaceuticals (ENTA): Here's What You Should Know
Zacks Investment Research
Enanta Pharmaceuticals Inc Stock (ENTA) Financials Data
Enanta Pharmaceuticals Inc (ENTA) Revenue 2024
ENTA reported a revenue (TTM) of $73.62 million for the quarter ending December 31, 2023, a -10.32% decline year-over-year.
Enanta Pharmaceuticals Inc (ENTA) Net Income 2024
ENTA net income (TTM) was -$138.24 million for the quarter ending December 31, 2023, a -14.60% decrease year-over-year.
Enanta Pharmaceuticals Inc (ENTA) Cash Flow 2024
ENTA recorded a free cash flow (TTM) of -$99.19 million for the quarter ending December 31, 2023, a +11.49% increase year-over-year.
Enanta Pharmaceuticals Inc (ENTA) Earnings per Share 2024
ENTA earnings per share (TTM) was -$6.56 for the quarter ending December 31, 2023, a -12.71% decline year-over-year.
Enanta Pharmaceuticals Inc Stock (ENTA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Vance Terry | Director |
Dec 13 '23 |
Sale |
9.12 |
15,295 |
139,490 |
5,800 |
| Luly Jay R. | President and CEO |
Dec 05 '23 |
Sale |
9.63 |
7,230 |
69,625 |
806,793 |
| Gardiner Nathaniel S. | Sr. VP & General Counsel |
Dec 05 '23 |
Sale |
9.63 |
2,412 |
23,228 |
68,154 |
| MELLETT PAUL J | Sr. VP, Finance & Admin. & CFO |
Dec 05 '23 |
Sale |
9.63 |
2,412 |
23,228 |
93,549 |
| Or Yat Sun | Sr. VP, R&D & CSO |
Dec 05 '23 |
Sale |
9.63 |
2,412 |
23,228 |
370,695 |
| Luu Brendan | Sr. VP, Business Dev. |
Dec 05 '23 |
Sale |
9.63 |
2,125 |
20,464 |
36,736 |
| Kieffer Tara Lynn | Sr. VP, New Prod. Strat. & Dev |
Dec 05 '23 |
Sale |
9.63 |
2,125 |
20,464 |
37,260 |
| Rottinghaus Scott T. | Sr. VP & CMO |
Dec 05 '23 |
Sale |
9.63 |
534 |
5,142 |
26,466 |
About Enanta Pharmaceuticals Inc
Enanta Pharmaceuticals, Inc., a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and hepatitis B virus. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.
0.20%
0.60%
Cap:
|
Volume (24h):